Checkpoint inhibitors have revolutionized cancer treatment by enhancing T-cell responses against tumors, leading to long-term tumor regression. These inhibitors, including anti-PD-1/PD-L1 and ...
Officials at BioAgilytix say the company has advanced its growth strategy with multi-million-dollar investments in liquid chromatography–mass spectrometry (LC/MS) capabilities, including new platforms ...
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics technology company redefining ...
Thought LeadersEdoardo FabiniPrincipal Scientist Evotec U.K. G-protein-coupled receptors (GPCRs) play a pivotal role in cellular signaling and have long been a major focus in drug discovery. These ...
Immune checkpoint inhibitors (ICIs) are widely used for cancer immunotherapy; however, the clinical efficacy of anti-PD-1/PD-L1 monotherapy is generally limited, highlighting the need to develop ...
A new article in the journal Nucleic Acid Therapeutics addresses the recognition by the U.S. Food and Drug Administration that immunogenicity assays may be necessary to measure immune responses to ...
CN Bio, a leading provider of Organ-on-a-chip (OOC) Systems and solutions that accelerate drug discovery and development workflows, today announced the launch of its PhysioMimix ® DILI assay kit: ...
PELSA allows for systematic analysis of ligand-binding proteins, their binding sites, and local binding affinities in cell lysate. Credit: DICP PELSA is a sensitive, versatile method for identifying ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results